(Q35943499)

English

Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

11 August 2017

Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial (English)

1 reference

Europe PubMed Central

11 August 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

diabetic macular edema

1 reference

based on heuristic

inferred from title

Diabetic Retinopathy Clinical Research Network

13

object named as

Diabetic Retinopathy Clinical Research Network

1 reference

Europe PubMed Central

11 August 2017

Adam R Glassman

2

object named as

Adam R Glassman

1 reference

Europe PubMed Central

11 August 2017

4

object named as

Lee M Jampol

1 reference

Europe PubMed Central

11 August 2017

Neil M. Bressler

5

object named as

Neil M Bressler

1 reference

Europe PubMed Central

11 August 2017

Susan B Bressler

6

object named as

Susan B Bressler

1 reference

Europe PubMed Central

11 August 2017

12

object named as

Roy W Beck

1 reference

Europe PubMed Central

11 August 2017

author name string

John A Wells

1

1 reference

Europe PubMed Central

11 August 2017

Allison R Ayala

3

1 reference

Europe PubMed Central

11 August 2017

Alexander J Brucker

7

1 reference

Europe PubMed Central

11 August 2017

Frederick L Ferris

8

1 reference

Europe PubMed Central

11 August 2017

G Robert Hampton

9

1 reference

Europe PubMed Central

11 August 2017

Chirag Jhaveri

10

1 reference

Europe PubMed Central

11 August 2017

Michele Melia

11

1 reference

Europe PubMed Central

11 August 2017

language of work or name

0 references

publication date

25 February 2016

1 reference

Europe PubMed Central

11 August 2017

1 reference

Europe PubMed Central

11 August 2017

123

1 reference

Europe PubMed Central

11 August 2017

6

1 reference

Europe PubMed Central

11 August 2017

1351-1359

1 reference

Europe PubMed Central

11 August 2017

Intravitreal Aflibercept for Diabetic Macular Edema: 100-Week Results From the VISTA and VIVID Studies.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4877252

2 October 2017

Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4877252

2 October 2017

Cardiovascular events and bleeding risk associated with intravitreal antivascular endothelial growth factor monoclonal antibodies: systematic review and meta-analysis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4877252

2 October 2017

Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4877252

2 October 2017

Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4877252

2 October 2017

Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4877252

2 October 2017

Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4877252

2 October 2017

Multiple imputation: a primer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4877252

2 October 2017

Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4877252

2 October 2017

Comparative Effectiveness Trial for Diabetic Macular Edema: Three Comparisons for the Price of 1 Study From the Diabetic Retinopathy Clinical Research Network

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4877252

24 September 2018

Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4877252

24 September 2018

Easy SAS calculations for risk or prevalence ratios and differences

1 reference

https://pubmed.ncbi.nlm.nih.gov/26935357

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1016/J.OPHTHA.2016.02.022

1 reference

Europe PubMed Central

11 August 2017

1 reference

Europe PubMed Central

11 August 2017

1 reference

Europe PubMed Central

11 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35943499&oldid=2050978969"